Effect of N-acetylcysteine (NAC) on Hydrogen Sulfide (H2S) in Chronic Kidney Disease (CKD)

Effect of N-acetylcysteine on Hydrogen Sulfide in Chronic Kidney Disease

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01232257

Enrollment

Registered

2010-11-02

Start date

2011-07-31

Completion date

2011-12-31

Last updated

2012-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease, Chronic Kidney Failure, End Stage Kidney Disease, End Stage Renal Disease

Keywords

Chronic kidney disease, Chronic kidney failure, End stage kidney disease, End stage renal disease, Hydrogen sulfide, N-acetylcysteine, Acetylcysteine

Brief summary

Cardiovascular morbidity and mortality is high in CKD patients. Nitric oxide (NO) deficiency plays a crucial role in progression of CKD. This leads to endothelial dysfunction, hypertension, and inflammation. Hydrogen sulfide (H2S) could serve as a backup mechanism for NO deficiency in CKD. N-acetylcysteine (NAC) is a derivate of cysteine and this is the main substrate for H2S production. Therefore, NAC should enable us to stimulate H2S production in humans. Our objective is to investigate the effect of NAC on plasma H2S levels and on markers of oxidative stress, inflammation, and endothelial dysfunction in healthy volunteers, CKD patients, and dialysis patients. We hypothesize that there is an increase in H2S levels after treatment with NAC.

Interventions

DRUGN-acetylcysteine

4 gifts of N-acetylcysteine 600 mg BID

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Healthy volunteers: * Adult (\> 18 years and older) * Healthy, as assessed by medical history, blood pressure, plasma creatinine, and urine dipstick * No medication use CKD patient: * Adult (\> 18 years and older) * CKD stage 3-4 (GFR 15-60 ml/min) Hemodialysis patient: * Adult (\> 18 years and older) * Hemodialysis patient Peritoneal dialysis patient: * Adult (\> 18 years and older) * Peritoneal dialysis patient

Exclusion criteria

* Unable to give informed consent * Hypersensitivity to N-acetylcysteine * Pregnancy

Design outcomes

Primary

Measure	Time frame	Description
Hydrogen sulfide (H2S)	After 48 hours	Investigate the effect of N-acetylcysteine on plasma H2S levels and on markers of oxidative stress, inflammation, and endothelial dysfunction in healthy volunteers, CKD patients, and dialysis patients

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026